Page 12 - Complete Response News Today

Jul 07 2021 STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major companion animal markets of the US, Europe, and the United Kingdom. STELFONTA® will be available to Australian veterinarians, including oncologists and general practitioners, in October 2021 thro...

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 a

TORONTO, May 28, 2021 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage…

In CheckMate -577, Opdivo 1 Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer 1 PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Appendix 4C Quarterly Activity Report Mesoblast LimitedApril 30, 2021 GMT NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. “We are very excited abo...

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study News provided by Share this article BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 /PRNewswire/ --  Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial (NCT04268706) in relapsed / r...

Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Companys Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non...

To embed, copy and paste the code into your website or blog: An appellate court upheld a judgment that clever omissions from statements made by a corporate officer constituted securities fraud. On January 22, 2021, the U.S. Court of Appeals for the First Circuit in Boston, Massachusetts upheld a jury’s fraud verdict against an executive in a securities case tried in the U.S. District Court for the District of Massachusetts. 1  In a 30-page opinion, the Court in SEC v. Johnston 2  refused t...

Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (" UA") has received site Institutional Review Board ...

Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology (" VU") has received site Institutional Review Board (" IRB")...